Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance

Table 2 Relationship of Antibiotic susceptibility with Erava MIC value levels in MSSA isolates.

Antibiotic	N	Resistance rate^a (%)	MIC breakpoints (mg/L)	No. isolates each level	Erava MIC (mg/L) data
					No. isolates with each MIC				MIC₅₀/MIC₉₀
					≤0.125	0.25	0.5	1.0	MIC₅₀/MIC₉₀
Total	190			189	92	66	29	3	0.25/0.5
Amikacin	182	3.85	≤16	174	85	59	28	3	0.25/0.5
			32	5	3	2	0	0	0.125/0.25
			≥64	2	2	0	0	0	ND
Erythromycin	186	73.66	≤0.5	48	43	1	4	0	0.125/0.5
			1–4	3	1	1	0	1	0.25/1
			≥8	134	46	63	24	2	0.25/0.5
Ciprofloxacin	181	8.84	≤1	164	93	49	20	2	0.125/0.5
			2	1	0	1	0	0	ND
			≥4	15	5	2	8	1	0.25/0.5
Rifampicin	185	4.32	≤1	176	88	61	26	2	0.25/0.5
			≥4	8	2	3	2	1	0.25/0.5
Tetracycline	188	39.89	≤4	112	76	27	8	1	0.125/0.25
			8	11	4	5	2	0	0.25/0.5
			≥16	64	10	34	19	2	0.25/0.5
Tobramycin	172	39.53	≤4	103	60	29	13	1	0.125/0.5
			8	1	0	0	1	0	ND
			≥16	67	24	28	14	2	0.25/0.5
Quinupristin	161	1.86	≤1	157	78	50	28	2	0.125/0.5
			2	1	0	1	0	0	ND
			≥4	2	1	1	0	0	ND

ISSN: 1471-2180